<p>This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine.</p><p>If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the scientific discussion (also part of the EPAR).</p>
Therapeutic Indication
<div class="subsection mt-3-5"> <h3>Therapeutic indication</h3><ul><li>Treatment of invasive candidiasis in adult or paediatric patients;</li> <li>treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin B, lipid formulations of amphotericin B and / or itraconazole. Refractoriness is defined as progression of infection or failure to improve after a minimum of seven days of prior therapeutic doses of effective antifungal therapy;</li> <li>empirical therapy for presumed fungal infections (such as <em>Candida</em> or <em>Aspergillus</em>) in febrile, neutropaenic adult or paediatric patients.</li> </ul></div>
Therapeutic Area (MeSH)
ATC Code
J02AX04
ATC Item
N/A
Pharmacotherapeutic Group
Antimycotics for systemic use
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| caspofungin (as acetate) | N/A | caspofungin (as acetate) |
EMA Name
Cancidas (previously Caspofungin MSD)
Medicine Name
Cancidas (previously Caspofungin MSD)
Aliases
N/ANo risk management plan link.
